Jeffrey W. Albers is a corporate insider at Kymera Therapeutics, Inc. (KYMR). Albers's filing history also covers Spyre Therapeutics, Inc. (SYRE) and Blueprint Medicines Corp (BPMC). Albers has reported 10 insider filings with the SEC since 2024. The most recent filing was in June 2026.
Every role Jeffrey W. Albers has reported on a Form 4, reconstructed from the filings themselves. Reporting insiders must state their relationship to the issuer (officer title, director seat, or 10% ownership) on every filing.
Spyre Therapeutics, Inc. (SYRE)1 filingKymera Therapeutics, Inc. (KYMR)1 filingUpdated Aug 30, 2026
Jeffrey W. Albers is Director of Spyre Therapeutics, Inc. (SYRE). 10 SEC Form 4 filings on record going back to 2024, most recently on 11 August 2026. Most recent open-market trade: sold $1.05M of SYRE on 11 August 2026. Lifetime open-market sales: $5.26M.
Every recent SEC Form 4 transaction Jeffrey W. Albers has reported, most recent first.
InsiderAlpha's records for Jeffrey W. Albers go back to 2024: 10 primary Form 4 filings, an average of 3.3 per year. 23 recorded transactions carry a Rule 10b5-1 flag, meaning they were pre-scheduled under a written trading plan rather than discretionary.
Insiders who reported open-market trades in the last 12 months at the companies Jeffrey W. Albers files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
Other corporate insiders with significant SEC Form 4 track records on InsiderAlpha:
Jeffrey W. Albers is a corporate insider, tracked as Director of Spyre Therapeutics, Inc. (SYRE). InsiderAlpha holds 10 primary Form 4 filings for them, the earliest from 2024, updated as new SEC EDGAR filings are processed.
2 primary Form 4 filings in the last 90 days, covering 2 companies.
Recorded transactions: 0 open-market purchases and 13 open-market sales ($5.26M) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
A free account opens the full scored daily plan and every past day, a watchlist for any ticker, and 3 months of price history on every company page. No card.
Free plan available · Paid plans start with a 7-day free trial